Pharmacovigilance in Pneumonia: Drug Safety Across Patient Demographics

Pneumonia remains a significant global health concern, contributing to substantial morbidity and mortality across diverse patient populations. While antimicrobial therapy is the cornerstone of treatment, drug safety issues, such as adverse drug reactions (ADRs), antimicrobial resistance, and drug-drug interactions, pose critical challenges for optimal patient outcomes. Pneumonia is commonly treated with strong antibiotics, which can sometimes cause side effects in patients. This review combines hospital findings with research evidence to identify which drugs are more likely to cause adverse reactions. Most reactions were mild and improved with proper monitoring and timely changes in treatment. The study highlights the importance of pharmacovigilance in ensuring safe and effective pneumonia management. Pharmacovigilance plays a pivotal role in monitoring and evaluating these safety concerns, especially in varied demographic groups including children, older adults, immunocompromised individuals, and patients with comorbidities. This study examines post-marketing safety data related to pneumonia therapies, analyzing ADR trends, severity, and causality across demographic subgroups. Preliminary findings highlight age-related differences in susceptibility to ADRs, with elderly patients experiencing a higher incidence of cardiotoxic and nephrotoxic events, while pediatric populations exhibited more hypersensitivity reactions. Socioeconomic factors, polypharmacy, and genetic variability further influence drug safety profiles. These insights underscore the need for demographic-specific pharmacovigilance strategies and tailored prescribing practices to improve safety outcomes in pneumonia management. Enhanced real-world evidence generation, active ADR reporting, and integration of demographic-specific risk mitigation approaches are recommended to strengthen drug safety surveillance in pneumonia treatment. Doctors have several ways to check how serious pneumonia is, which helps them decide further care. Viruses can also cause pneumonia, so spotting them early is important to start the right treatment quickly. For community-acquired pneumonia, doctors usually recommend a combination of a beta-lactam antibiotic and a macrolide, or they may use a respiratory fluroquinolone on its own.